HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck & Co., Inc.

http://www.merck.com

Latest From Merck & Co., Inc.

Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive

The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.

China Research & Development

Project 5 In 5: US FDA Oncology Office Seeks Pragmatic Trial Proposals From Clinicians, Patients

Industry has been slow to embrace the idea of pragmatic clinical trials with streamlined data collection, so the Oncology Center of Excellence now is turning to the broader cancer community for research proposals.

Clinical Trials Post Market Regulation & Studies

Calliditas Confident Of Setanaxib's Potential Despite Unclear Data

The Sweden-headquartered biotech has emphasized the promising survival data in a head and neck cancer study of setanaxib rather than the NOX inhibitor’s inability to shrink tumors.

Cancer Clinical Trials

Gossamer Partners With Chiesi To Accelerate Seralutinib Development

Already in Phase III for PAH, Gossamer said it can take seralutinib into Phase III for PH-ILD at least four years earlier than planned under its alliance with respiratory disease expert Chiesi.

Deals Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Abmaxis
    • Acacia Biosciences
    • Acceleron Pharma Inc.
    • Afferent Pharmaceuticals
    • ArQule, Inc.
    • Avecia Biologics Limited
    • Banyu Pharmaceutical Co., Ltd.
    • Calporta Therapeutics
    • cCAM Biotherapeutics Ltd.
    • Cubist Pharmaceuticals, Inc. (Adolor Corporation (ADLR)
    • Calixa Therapeutics, Inc.
    • Optimer Pharmaceuticals, Inc.
    • Trius Therapeutics, Inc.)
    • Idenix Pharmaceuticals, Inc.
    • Immune Design Corporation
    • Inspire Pharmaceuticals, Inc.
    • IOmet Pharma
    • iOnctura SA
    • Integrated Therapeutics Group
    • Merck Sharp & Dohme (MSD) Pharmaceuticals Pvt. Ltd.
    • MSD
    • MSD K.K. (Japan)
    • Nobilon International BV
    • Novacardia
    • OncoEthix SA
    • OncoImmune, Inc.
    • Organon BioSciences
    • Peloton Therapeutics, Inc.
    • Pandion Therapeutics, Inc.
    • Rigontec GmbH
    • Schering-Plough Corporation
    • SmartCells, Inc.
    • Tilos Therapeutics, Inc.
    • Vallee S.A.
    • Viralytics Limited (ASX:VLA)
    • Themis Biosciences GmbH
UsernamePublicRestriction

Register